Regenerative Medicine company Precise Bio. is launching a dedicated ophthalmology business unit to advance the use of bio-printed tissues and organs in the field.
Background
Precise Bio has developed an innovative 4D-bio-fabrication technology that is a true platform for innovation and comprises cell expansion, bio-materials, processes, printing technology and other required critical technologies. The company claims its platform is able to generate complex tissues in a highly reproducible manner and to apply lessons learned from the fabrication of one tissue to the next. This allows for rapid innovation and product development, and provides a foundation on which to build a robust pipeline of proprietary products with substantial clinical and commercial value. This platform can solve critical limitations of existing 3D bio-fabrication technologies and is paving the way for the engineering of more complex tissues and organs.
Precise Bio is the first company to transplant a 3D-printed cornea graft in animals. Results of the initial study support the feasibility, safety and efficacy of Precise Bio’s novel technologies and establish a foundation for future development and progress toward human trials. The company’s robust technology platform allows it to advance its printed human cornea program concurrent with the development of other organs and tissues for use in ophthalmic indications. This comprises a broad array of possibilities including retinal patch, vision correction lenticules, solutions for ocular surface diseases and others.
Company comments
Making its announcement at the annual meeting of the American Academy of Ophthalmology (AAO), taking place October 27-30, 2018 in Chicago, Precise Bio’s CEO and co-founder Aryeh Batt said “There has been great excitement among physicians and commercial organizations about our disruptive technology to create eye-related tissues and its potential to transform the treatment of serious ophthalmic diseases and conditions.
“Based in part on the requests and suggestions from these key audiences, we are currently pursuing different ophthalmic programs, two of which are being undertaken with collaborators. As the first company to transplant a 3D-printed corneal graft in animals, we are uniquely positioned to advance the use of bio-printed tissues in ophthalmology. Establishing a business unit dedicated to realizing this potential will support our future financing strategies and ensure that our financial resources are aligned with the tremendous power of our technology and intellectual property in a market with an estimated cumulative value of $10 billion.”
“Precise Bio’s technology has the potential to truly transform the treatment of serious diseases, and to address the unmet needs in corneal replacement and other indications, which cannot be met by the limited number of donor tissues and organs,” said Shay Soker, PhD, Professor at the Wake Forest Institute of Regenerative Medicine (WFIRM) and a co-founder of Precise Bio. “The company’s technology overcomes multiple challenges in scalable, reproducible manufacturing of bio-printed tissues and organs, and positions Precise Bio for leadership in the field of regenerative medicine.”
Source: Globe Newswire
